Cigna signs value contracts for new cholesterol drugs; Yelp partners with ProPublica for hospital reviews; ad-blocking threat to digital publishers intensifies
Amgen takes issue with yet-to-be published multiple-myeloma drug report
Novo’s Tresiba gets non-preferred status; Valeant’s head of dermatology and gastrointestinal products resigns; Trump plans to allow importation of drugs from abroad
It’s possible that payers won’t prove the wild card in the PCSK9 derby. Instead, physician preference may do more to shape the market and maybe even force payers’ hands.
We look forward to collaborating with stakeholders across the healthcare system—including PBMs—to extend success to disease states beyond hepatitis C, writes PhRMA CEO Stephen Ubl.
Britain says Bristol-Myers Squibb’s Opdivo is too expensive; Calpers reports 32% boost in specialty drug spending; NIH is funding fewer clinical trials